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Abstract: Lung transplant recipients require life-long profound immunosuppression, making them prone
to respiratory tract infections (RTIs), in particular viral infections, during the winter season. Since
RTIs may have severe consequences, of which acute or chronic allograft dysfunction is feared most,
early diagnosis and treatment are recommended. Patients monitor lung function daily at home and are
instructed to contact the transplant center in case of signs and symptoms suspicious of RTIs. We then
obtain nasopharyngeal swabs for viral and bacteriological examination and initiate pre-emptive treatment
with antivirals, broadband antibiotics, and sometimes intravenous immunoglobulins. Treatment duration
is guided by virology sampling results. As preventive measures, we provide vaccination against seasonal
influenza for patients and household contacts and recommend specific daily hygiene measures.
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Abstract
Lung transplant recipients require life-long profound immunosup-
pression, making them prone to respiratory tract infections (RTIs), 
in particular viral infections, during the winter season. Since RTIs 
may have severe consequences, of which acute or chronic allograft 
dysfunction is feared most, early diagnosis and treatment are re-
commended. Patients monitor lung function daily at home and are 
instructed to contact the transplant center in case of signs and symp-
toms suspicious of RTIs. We then obtain nasopharyngeal swabs for 
viral and bacteriological examination and initiate pre-emptive tre-
atment with antivirals, broadband antibiotics, and sometimes intra-
venous immunoglobulins. Treatment duration is guided by virology 
sampling results. As preventive measures, we provide vaccination 
against seasonal influenza for patients and household contacts and 
recommend specific daily hygiene measures.
Keywords: Antibiotic, antivirals, immunosuppression, lung 
transplantation, viral infection
Özet
Akciğer nakil olguları, hayat boyu yoğun bir immünsuresif tedavi al-
mak zorundadırlar. Bu tedavi onları, özellikle kış döneminde, başta vi-
ral nedenler olmak üzere, solunum yolu enfeksiyonlarına (SYE) yatkın 
hale getirir. Solunum yolu enfeksiyonlarının, akut veya kronik allograft 
rejeksiyonu gibi çok ağır ve korkulan sonuçları olabileceği için, erken 
tanı ve tedavi önerilmektedir. Tüm akciğer nakil olguları evlerinde gün-
lük solunum fonksiyonu takibi yaparlar. Bu takip sırasında SYE şüphesi 
doğuracak semptom ve bulgular görüldüğünde nakil merkezi ile he-
men bağlantı kurmaları konusunda eğitimlidirler. Nakil merkezine SYE 
şüphesi ile başvuran hastadan viral ve bakteriyolojik inceleme için na-
zofarengeal sürüntü alınır. Sonrasında önlem olarak geniş spektrumlu 
antibiyotik, antiviral ve intravenöz immünglobülin tedavi başlanır. Te-
davi süresi virolojik örneklemelerin sonuçlarına göre belirlenir. Ayrıca 
SYE’den korunmak için tüm nakil olgularımıza ve ev içi temaslılarına 
mevsimsel influenza aşısı yapılır ve özel hijyen önlemleri önerilir.
Anahtar Kelimeler: Akci ğer transplantasyonu, antibiyotik, antiviral, 
immünosüpresyon, viral enfeksiyon
INTRODUCTION
Lung transplantation is an established therapy for end-stage non-malignant pulmonary disease. 
Long-term survival rates are inferior than for other solid organ transplant recipients (SOTRs), with the 
overall median survival being slightly more than 5 years. The most important long-term complication 
is the development of chronic lung allograft dysfunction (CLAD), most commonly presenting as bron-
chiolitis obliterans syndrome (BOS). This development is, at least in part, due to inflammation in the 
small airways that results in structural and functional changes of the lung with an obstructive airway 
pattern. The etiology of BOS and its pathogenesis are incompletely understood. Triggers of inflam-
matory reactions, such as repeated acute rejection episodes or respiratory tract infections, however, 
appear to be contributing factors. 
Lung transplant recipients (LTRs) are more susceptible to infections in comparison to other SOTRs, 
which implicates a greater impact of respiratory tract infections (RTIs) on the long-term functional 
outcome (1, 2). For these reasons, infectious complications are feared in these severely immunosup-
pressed individuals (3, 4). A causative link between viral infections and rejection has long been as-
sumed (5). To date, no study has been able to prove that a particular respiratory virus infection is 
directly linked to either acute rejection or the development of CLAD. The development of CLAD ap-
pears to be more likely a process of unspecific inflammatory reactions triggered by RTIs rather than vi-
rus-specific factors (6). A number of studies have shown that RTIs of viral origin are associated with the 
development of BOS as long-term sequelae. A few authors have described acute rejection episodes in 
LTRs associated with certain viral RTIs. This is in line with our own experience. However, the data sup-
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porting this link are controversial. It might be that a sequence of vari-
ous different RTIs is more likely to contribute to allograft dysfunction 
over time, and some RTIs may be more prone to trigger this develop-
ment than others. In addition, susceptibility to this development may 
vary among LTRs, and there may be other contributing factors that 
promote this development, such as gastro-esophageal reflux disease 
with associated microaspirations. Further, prospective studies are 
expected to elucidate these issues. In the meantime, many experts 
consider early diagnosis and treatment of RTI is of crucial importance 
to prevent the potentially serious sequelae of these infections. 
Immunosuppression puts LTRs at increased risk for viral infections. 
Prophylactic medication for cytomegalovirus (CMV) infections, which 
is widely used at least for the first 3 months post-transplant and 
sometimes extended beyond this phase (e.g. at our center), protects 
patients largely from infections of the herpes family. The increased 
risk for the acquisition of community-acquired respiratory virus 
(CARV) in LTRs is due to the life-long profound immunosuppression 
and the fact that the transplanted organ is in direct contact with the 
environment. Denervation, a reduced cough reflex, and subsequent 
impaired mucociliary clearance further increase the risk of severe 
pulmonary infections. Infections with CARV influence the acute and 
chronic morbidity and mortality of LTRs (7, 8). In this article, we out-
line the diagnostic and therapeutic strategies used at our institution 
to reduce the impact of these viruses on the outcome of LTRs. Due to 
the limited literature in the field of practical management and lack 
of evidence for many of these procedures, our recommendations are 
largely based on experience.
Clinical and Radiologic Presentation
There is significant overlap of the symptoms of CARV infections, and 
it is difficult to distinguish clinically which respiratory virus is causing 
symptoms in a given patient. Common symptoms include cough, 
rhinorrhea, and dyspnea (Table 1). Viral infections often involve the 
upper respiratory tract. Progression of the viral infection to the lower 
respiratory tract is observed more frequently in immunosuppressed 
patients and is difficult to be differentiated from other viral co-infec-
tions or bacterial super-infections (9). 
Progression from upper respiratory infection to lower respiratory in-
fection is generally associated with more severe disease and, proba-
bly, with more serious short and long-term consequences. The risk of 
progression to lower tract disease is not well defined; however, it is 
likely to be dependent on the post-transplant time, intensity of im-
munosuppression, and type of virus.
The chest radiograph is non-specific and may show diffuse intersti-
tial infiltrates but can also show airspace disease. The most common 
chest computed tomography finding is ground-glass attenuation; 
centrilobular nodules measuring 3 to 10 mm, including a tree-in-bud 
appearance, can also be seen (9). 
Due to immunosuppression, the clinical status and condition of the 
transplant recipient at presentation are not good indicators of dis-
ease severity. This means that initially clinically well-appearing LTRs 
with no or minor signs of URTI may experience a rapid decline in 
FEV1, which may go unnoticed unless pulmonary function tests are 
performed. Many centers recommend lung function self-monitoring, 
which is able to detect even minor or asymptomatic changes in lung 
function (200 mL or 10%).
Suggestive symptoms of RTIs are throat pain or pain on swallowing, 
rhinorrhea, (dry) cough, fever, and myalgias (10). In LTRs, a number 
of symptoms should be considered as possible indicators for an ear-
ly stage of infection, since oligosymptomatic infections do occur. 
Gastrointestinal symptoms, such as nausea, vomiting, and diarrhea, 
have been reported, for example, in patients with influenza infection 
(11). In adenovirus infection, hepatitis can occur; in kidney transplant 
recipients, hemorrhagic cystitis has been reported. Possible clinical 
presentations are summarized in Table 1. If one or more of these 
symptoms are noted, we recommend contacting the transplant cen-
ter by telephone as soon as possible (within hours) to minimize the 
diagnostic delay and initiate empirical therapy. 
Virus Biology
At our transplant center, we test for the following viral pathogens 
when a respiratory tract infection is suspected: adenovirus, human 
bocavirus, corona virus, enterovirus, influenza virus, parainfluenza 
virus, human metapneumovirus, rhinovirus, and human respiratory 
syncytial virus (RSV). With the exception of adenovirus and bocavirus, 
these CARVs are single-stranded RNA viruses and show a predomi-
nantly seasonal appearance during the winter months (Table 2).
The symptoms of an RTI are often unspecific and potentially discrete. 
Symptoms of influenza infection have been well described for immuno-
competent individuals, which affect 5%-20% of the population predom-
inantly during the winter season. Conversely, the classical “influenza-like 
illness,” with sudden onset of symptoms, including fever, dry cough, 
throat pain, myalgias, or headache, is, in most cases, not observed in its 
full presentation in LTRs. In symptomatic patients, the influenza virus is 
detected 5 times more often than when symptoms are absent (12).
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Symptoms
 Throat irritation or pain, swallowing pain
 Sneezing
 Rhinorrhea/nasal obstruction
 Cough with or without sputum production






-spirometric Reduction in FEV1 within 24 hours by 200 ml or  
 10% (the smaller value is recommended as limit)
- radiologic Change in chest x-ray or computed tomography  
 (opacity or effusion)
 (we usually do not routinely perform chest  
 imaging in these situations)
- Lab findings Raised inflammatory markers (CRP, leukocytes)  
 without other focus
FEV
1
, forced expiratory volume in first second; CRP: C-reactive protein.
Table 1. Symptoms and signs of respiratory viral infections
The association of viral infections with acute and chronic rejection is 
best described for infections with paramyxoviridae [parainfluenza virus 
(PIV), respiratory syncytial virus (RSV), and human metapneumovirus 
(HMPV)]. PIV belongs to the most frequently detected viruses among 
LTRs, and the associated risk of chronic rejection has been considered 
to be high. RSV infections are highly contagious, and the mortality in 
LTRs has been reported to be elevated (4%-33% of patients in pub-
lished series of patients receiving treatment). HMPV infection is often 
limited to the upper airways. When progression to the lower airways 
occurs, it is associated with severe disease progression (2). Rejection 
episodes have been documented following HMPV infections in LTRs. 
Rhinovirus and enterovirus belong to the family of picornaviridae. 
Rhinovirus infections were the most frequently observed infections 
observed in our cohort of LTRs, and prolonged virus shedding for up 
to a few months has been observed (13). 
Approximately one-third of these infections are asymptomatic (14). 
Enterovirus infections might cause a syndrome that has been termed 
“summer flu;” it can, however, also cause severe entities, including 
meningoencephalitis and myocarditis.
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  Symptom  Allograft  Progression**/ 
Virus frequency dysfunction*  Season
Adeno ++ + +/Year-round
Boca + ? ?/Unclear significance
Corona ++  + 
Entero ? ? 
Influenza ++  ++ ++/Winter season/§
Metapneumo + ++ ?/Winter season/§
Rhino + +  +/Year-round
RSV ++ +++ Winter season
Parainfluenza ++ ++ Year-round
Parvo B19  ++ ? +/
*acute or chronic allograft dysfunction associated with infection or as a 
consequence of infection. **progression from upper to lower respiratory 
tract infection.
? unclear issue; + applicable/rare; ++ applicable/moderately frequent; 
+++ applicable/frequent; § increased mortality reported; RSV: respiratory 
syncytial virus
Table 2. Symptom frequency and consequences of viral respiratory 
tract infections in lung transplant recipients
Virus Therapeutic intervention/medication Second line therapy/ additional measures
Adeno Cidofovir, 3 mg/kg IV, 1x/week IVIG, Ribavirin (exp), RIS
Boca nst Unclear, (IVIG)
Corona nst IVIG, Ribavirin (exp)
Entero nst IVIG
Influenza Oseltamivir 75 mg BD, KF: 75 mg OD. Duration:  Zanamivir INH (2 puffs BD) Peramivir, IV, 
 extended treatment as long as virus is detectable.  Ribavirin (exp.) (IVIG if IgG<7 g/L)
Metapneumo Ribavirin first, 48 h: 400 mg BD, then 200 mg BD. IVIG Ribavirin IV *
RSV Ribavirin, first 48 h: 400 mg BD, then 200 mg BD (or INH) Palivizumab, IVIG, Ribavirin IV (cave: anemia)*
Rhino nst RIS, IVIG
Parainfluenza Ribavirin; first 48 h: 400 mg BD, then 200 mg BD. Recombinant Sialidase, * Fusion protein (FluDase)
Parvo B19  nst RIS, IVIG
*Consider increasing prednisone dose
BD: Twice daily; exp: experimental/being evaluated; IVIG: intravenous immunoglobulins; IgG: immunoglobulin G; INH: inhalative; IV: intravenous; KF: kidney 
failure (GFR<30 mL/min); nst: no specific therapy; OD: once daily; PO: by oral route; RIS: reduced immunosuppression recommended
Tablo 1. Specific therapeutic measures for viral respiratory tract infections
Figure 1. WBC, white blood cell count; CRP, C-reactive protein; 
NPS, nasopharyngeal swab
Approximately one-third of viral RTIs are caused by corona viruses. 
The SARS epidemic in 2002 was caused by a coronavirus, and the re-
cent emergence of a complicated RTI is derived from this family of 
viruses (MERS-CoV).
Adenovirus, bocavirus, and parvovirus B19 are DNA viruses. Adenovi-
ruses cause RTI in humans and are not limited to a certain season. They 
can also affect other organs, such as the eyes and gastrointestinal and 
urinary tracts. Human bocaviruses are associated with RTIs and gas-
troenteritis in children and adults. There are limited data on the im-
portance of this pathogen, in part because it is rarely detected in LTRs.
Diagnostic Tests and Meaning of Results
Diagnostic methods for the detection of CARV have evolved in the 
last decade, largely improving sensitivity and specificity and, impor-
tantly, reducing time to diagnosis. Current molecular diagnostic tests 
allow rapid simultaneous detection of a number of viruses by multi-
plex polymerase chain reaction (PCR). In patients with a symptomatic 
RTI, the most frequently detected viruses are: rhinovirus, parainflu-
enza virus, RSV, influenza virus, and coronavirus (14). Under certain 
circumstances, progression of the infection is more frequently ob-
served from the upper airways to the lower airways: infection with 
influenza, RSV, PIV, pediatric patients, profound immunosuppression, 
early post-transplant period, and in patients with very low lympho-
cyte counts (15). Early initiation of antiviral therapy may reduce the 
progression to the lower airways, for example, with oseltamivir for 
influenza infections. Diagnostics and therapy therefore must be di-
rected to these treatable viral infections. 
We attempt to obtain samples from the hypopharynx or nasophar-
ynx for PCR analysis and bacterial culture in order to identify the vi-
ral pathogen and possible bacterial co-infections, which may have 
implications on the treatment choice and duration. In severely im-
munosuppressed individuals, we frequently observe prolonged viral 
shedding of the virus, as detected by multiple consecutive PCR-posi-
tive results over extended durations. 
It remains to be determined whether this PCR positivity is an expres-
sion of viable virus or merely detection of envelope protein without 
virulence. In individual cases, the cell culture may be able to answer 
this question, whereby the question still remains on whether the de-
tected viable virus is to be considered “colonization” (i.e., persistence 
of virus in an asymptomatic patient). Infectivity from a clinical point 
of view would consider additional aspects, such as number of virions, 
ability to be mobilized from the location, and viability in the environ-
ment. Viral cultures are only performed if explicitly requested and jus-
tified, since these requests may be suppressed in some laboratories, 
since modern molecular methods, such as PCR, are generally consid-
ered to be sufficient for diagnosis, and in most cases, the viral culture is 
then considered to be obsolete/redundant. We require 2 negative PCR 
samples (taken on 2 different days, usually 1 week apart) to be nega-
tive before declaring the patient to be free of virus and abandon the 
isolation measures imposed during the active infection. These mea-
sures are implemented to prevent nosocomial transmission among 
outpatients and inpatients in the hospital setting.
Evaluation in Case of Suspected Respiratory Tract Infection
In case of symptoms and/or deterioration of home spirometry values, 
patients are instructed to contact the transplant center (Figure 1). The 
history taken is focused on symptoms, lung function measurements, 
presence of ill persons in the household, and contact with persons 
having signs of infection. In special situations (at night, inability to 
present at the hospital within a few hours due to lack of transport or 
large distance to the hospital), we instruct then to start empiric thera-
py immediately. In this case, the diagnostic workup is slightly delayed. 
Whenever possible, the diagnostic workup is performed on the same 
day in an emergency visit in our transplant outpatient clinic. The ob-
jective of this visit is to confirm the lung function measurement, which 
we perform with a handheld spirometer with a disposable mouthpiece 
and materials to assess the clinical status of the patient (inspection of 
the pharynx to note redness or secretions, verify nasal obstruction, and 
perform auscultation of the lungs). The sampling is performed for a 
virology examination by passing a plastic brush 2-3 times over a dis-
tance of 2-3 cm vertically along the back wall of the pharynx, putting 
the brush tip into the virus transport medium by breaking of the front 
half/tip while immersed in the transport medium, and discarding the 
part of the brush that was in contact with one’s hands. The lid of the 
transport medium must be firmly closed. We bend the shaft of the 
brush slightly prior to unpacking it in order to allow for a less irritating 
swab-sampling maneuver. The bacteriological swab, which is a cotton 
wool-like covered tip, is moved back and forth between the tonsils 
at the back wall of the pharynx (2-3 times) and is then stuck into the 
gel-like culture medium. Laboratory diagnostics include differential 
white blood count (to detect lymphopenia or leukopenia), C-reactive 
protein, and creatinine. In case of dominant nasal symptoms, the viral 
sampling is performed nasally, whereby the straight brush is inserted 
rapidly and horizontally by about 3-5 cm and is then retracted immedi-
ately before putting it in the transport medium. The physician or nurse 
obtaining the samples should wear a surgical mask and a visor or face 
guard during the procedure.
Therapy
The general therapy principles for lung transplant recipients with 
a suspected RTI are: a) consequent pre-emptive therapy with and 
broad-spectrum antibiotics; i.e., a respiratory quinolone, b) repeated 
applications of intravenous immunoglobulin (IVIG) in case of pro-
longed infections, and c) a moderate modification of the immuno-
suppressant therapy if possible. Evidence-based specific therapies 
exist only for a minority of CARVs: i.e., for influenza virus infections 
(oseltamivir) and for parainfluenza, RSV, and metapneumovirus in-
fections (ribavirin) (Table 3). Oseltamivir is given orally 75 mg BD (in 
case of kidney dysfunction with GFR<30 mL/h OD). Our dosing reg-
imen for oral ribavirin is 400 mg BD for the first 48h hours and then 
200 mg BD. The duration of the therapy is a matter of debate; some 
centers treat for 5-10 days, and we treat until 2 NPS samples are neg-
ative. For ribavirin, we monitor the full blood count weekly and dis-
continue the compound if adverse events are noted, such as anemia, 
nausea, or sleep disturbances.
Pre-Emptive Treatment
During the influenza season, we start oseltamivir (75 mg BD) in com-
bination with moxifloxacin (400 mg OD) empirically for patients with 
suspected respiratory tract infections (two or more signs or symp-
toms) pending the NPS results (virology/bacteriology). If the patient 
can not be seen on the same day, treatment is initiated prior to sam-
pling, and sampling is then performed the following day.
Intravenous Immunoglobulin (IVIG)
LTRs frequently have reduced immunoglobulin G levels after trans-
plantation. The hypogammaglobulinemia (defined in our setting as 
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IgG<7.0 g/L as the lower limit of normal) appears not to influence 
the incidence of CARVs (16). It is suggested that the administration 
of IVIG for CARV infection results in the transfer of specific antibodies 
directed against viruses and thus helps accelerate the resolution of 
the infection. In case of bacterial super-infection (for example, with 
Klebsiella), IVIG would also help in the treatment of this infection.
Modification of Immunosuppression
Infection and also prolonged viral shedding are sometimes signs 
of “over”-immunosuppression in these patients. In case of strong 
lymphopenia (<500 cells/uL) or leukopenia (<3000 cells/uL), we re-
duce the dose of immunosuppressants, commonly by reducing the 
antimetabolite. The reduction of mycophenolate mofetil is usually by 
one-third to one-half of the maintenance dose and is performed al-
ready when the respiratory tract infection is suspected (16). In case 
of progressive loss of lung function despite established antiviral and 
antibacterial therapy, we consider increasing the prednisone dose to 
counteract a possible inflammatory response. This would be consid-
ered in case of infections with orthomyxoviruses (PIF, RSV, metapneu-
movirus). Unlike others, we hardly ever give pulse steroid treatments 
in such situations, since our concept is primarily to treat the infection 
by all means and not to enhance immunosuppression additionally, 
which would further reduce the remaining immunological control of 
infection.
Prophylactic Measures to Prevent Respiratory Tract Infection
The recommendations provided here are based mainly on infection 
control measures suggested for seasonal influenza. Respecting these 
principles is also likely to prevent other CARV infections, and these 
measures might be considered to reflect universal precautions for re-
spiratory tract infections (17). Most CARVs are transmitted by direct 
contact or aerosolized droplets. Incubation periods range generally 
from 1 to 10 days (9). Asymptomatic shedding may occur in trans-
plant recipients. Both symptomatic and asymptomatic transplant re-
cipients may be considered “super-spreaders” of virus, given the high 
viral loads of respiratory viruses found in respiratory secretions. We 
recommend the following measures (18):
1. Yearly influenza vaccination as soon as the vaccine is locally 
available. US guidelines recommend vaccination after 3 months 
following transplantation. We vaccinate post-transplant accord-
ing to this timeline but preferably when the prednisone dose has 
been tapered to <20 mg/d. There is no good evidence for the op-
timal time point of vaccination or level of immunosuppressants 
influencing the vaccine response. The dose of the antimetabo-
lite (mycophenolate), however, appears to have the greatest ef-
fect on the immunological response after vaccination [19]. One 
should bear in mind that the influenza vaccine and presumably 
also other vaccines show a reduced immunological response 
after transplantation due to the profound immunosuppression, 
thus affecting the humoral response in cases of infection. The 
influenza vaccination has been shown to be safe and effective in 
LTRs. The vaccination is also recommended for close contacts of 
LTRs—in particular, household contacts and also health profes-
sionals caring for these patients.
2. High-risk situations, which could lead to infection with respirato-
ry viruses—for example, rush hour in shopping malls, restaurant, 
airports, train stations, or mass gatherings of persons in the cold 
season—should be avoided.
3. Frequent and consequent hand hygiene and cough etiquette 
(cough and sneezing into the elbow). Hand hygiene also entails 
disinfection after contact with public objects, such as door han-
dles, shopping carts, or railings.
5. Avoid contact with ill relatives and friends, in particular with ill 
children, as much as possible. If contact can not be avoided, one 
may consider the ill contact person to wear a mask and encour-
age hand hygiene.
6. Early contact with the transplant center (within hours) when the 
first signs of an infection occur in order to allow for diagnostic 
sampling and initiation of therapy. 
In summary, early self-referral of LTRs for microbiological sampling 
and initiation of pre-emptive treatment with oseltamivir and a 
quinolone or macrolide antibiotic during the influenza season aim to 
treat influenza infections early and limit the potential damage cause 
by these infections. Modification of treatment is performed 48 h later, 
when microbiological results are available by telephone consultation 
with patients. Selected other viruses are treated with antivirals and 
potentially intravenous immunoglobulins. Preventive measures are 
crucial for patients and relatives/close contacts in order to prevent 
infections in the first place.
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